Dr. Bookman named GOG ovarian committee chair

Michael A. Bookman, MD
Michael A. Bookman, MD

Michael A. Bookman, MD, section chief of Hematology/Oncology at the Arizona Cancer Center, has been appointed to chair the Ovarian Committee of the Gynecologic Oncology Group (GOG).

The GOG, which is designed to promote and perform clinical trials, new drug development and to establish new standards of care, is a part of the Clinical Trials Cooperative Group Program sponsored by the National Cancer Institute (NCI). These cooperative groups include researchers, cancer center members and community physicians who all come together with a common research focus. The GOG is the only such group dedicated to female pelvic cancers.

Dr. Bookman has been a member of the GOG for the past 20 years, and has served on a number of Committees, including Developmental Therapeutics, Medical Oncology, Protocol Development and Operations. He was most recently the chair of the Information Technology Committee.

As the chair of the Ovarian Committee, Dr. Bookman is responsible for overseeing large randomized studies that are involved in the treatment of literally thousands of ovarian cancer patients. That includes prioritizing and evaluating the key scientific and clinical questions that will improve the long-term outcomes for women with ovarian cancer, he said.

“I’m very passionate about clinical research; I think the national cooperative group program – particularly in gynecologic cancers – has been a huge success,” Dr. Bookman said. “Most of the standards of care have been developed through GOG, and I’m thrilled to be a part of that process and to try to carry it forward.”

“NCI sponsored collaborative groups, like the GOG, are imperative to achieving improved outcomes for women with gynecologic cancers because they try to address fundamental scientific and clinical questions within a trial, and are not limited to focusing on the registration and marketing of new drugs,” said Dr. Bookman.

“Dr. Bookman came to the Arizona Cancer Center in 2009 after serving 21 years at the Fox Chase Cancer Center in Philadelphia, most recently as vice president for Ambulatory Care and Clinical Research. He is a renowned expert in gynecologic medical oncology with a focus on the development of new treatments for gynecologic cancers,” said David S. Alberts, MD, director of the Arizona Cancer Center.

Dr. Alberts chairs the Cancer Prevention and Control Committee of the GOG, a committee he founded in 1994. The Arizona Cancer Center enters patients on GOG clinical trials through affiliation memberships with leadership from Setsuko Chambers, MD, director of gynecological oncology and women’s cancer, and Francisco Garcia, MD, co-director of the AZCC’s Cancer Health Disparities Institute, and Dr. Bookman.

Formed in 1970 by a group of gynecologic surgeons, the GOG has completed more than 300 clinical trials and registers more than 3,300 patients each year in GOG research trials. The GOG is a non-profit organization with the purpose of promoting excellence in the quality and integrity of clinical and basic scientific research in the field of gynecologic malignancies. Visit www.gog.org for more information.